AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36344933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for prediction of severe CAP development based on chronic kidney dysfunction, malignant tumor, abnormal neutrophil count, abnormal lymphocyte count, decreased serum albumin level, and increased HbA1c level at admission.
Number of subjects: 1026
Study 36344933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for prediction of severe CAP development
Number of subjects: 1026
Study 33164978 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted exercises plus general exercise recommendations
Number of subjects: 18
Study 33164978 — intervention group
Group type: COMPARATOR
Intervention: General exercise recommendations
Number of subjects: 18
Study 34347237 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous erector spinae plane block (ESPB)
Number of subjects: 80
Study 34347237 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 80
Study 33348088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning questionnaire from the Medical Outcome Study (MOS)
Number of subjects: 546
Study 33348088 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-C30 cognitive functioning (CF) subscale
Number of subjects: 546
Study 33348088 — intervention group
Group type: EXPERIMENTAL
Intervention: NCF test scores
Number of subjects: 546
Study 35229694 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Sentry handpiece + Intrepid Hybrid tip (Group 1)
Number of subjects: 168
Study 35229694 — intervention group
Group type: COMPARATOR
Intervention: Centurion Ozil handpiece + Intrepid Balanced tip (Group 2)
Number of subjects: 168
Study 35229694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 168
Study 32100261 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a or PegIFNα-2b (48-week treatment)
Number of subjects: 727
Study 34412009 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel quantitative digital image analysis methodology (DYNAMIKA®)
Number of subjects: 0
Study 34412009 — intervention group
Group type: EXPERIMENTAL
Intervention: Images with good quality scores
Number of subjects: 0
Study 34412009 — intervention group
Group type: COMPARATOR
Intervention: RA Magnetic Resonance Imaging Score (RAMRIS)
Number of subjects: 0
Study 32406725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit (n=101)
Number of subjects: 262
Study 32406725 — intervention group
Group type: COMPARATOR
Intervention: Control (n=161)
Number of subjects: 262
Study 35833083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided brachial plexus block anesthesia
Number of subjects: 82
Study 35833083 — intervention group
Group type: COMPARATOR
Intervention: Conventional anatomic localization brachial plexus block anesthesia
Number of subjects: 82
Study 35816301 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based prediction method
Number of subjects: 557
Study 35816301 — intervention group
Group type: COMPARATOR
Intervention: General Movement Assessment (GMA) tool
Number of subjects: 557
Study 35816301 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning method
Number of subjects: 557
Study 35816301 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning prediction model
Number of subjects: 557
Study 34047235 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 minutes) + Aerobic Exercise (30 minutes cycling at moderate intensity)
Number of subjects: 20
Study 34047235 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (10 s) + Aerobic Exercise (30 minutes cycling at moderate intensity)
Number of subjects: 20
Study 35236650 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine combined with methimazole
Number of subjects: 102
Study 35236650 — intervention group
Group type: COMPARATOR
Intervention: Methimazole treatment alone
Number of subjects: 102
Study 32479160 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide prevention PSAs (three different PSAs)
Number of subjects: 349
Study 32479160 — intervention group
Group type: COMPARATOR
Intervention: Control PSA
Number of subjects: 349
Study 32795310 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil (CO) 25 mL/day for 6 weeks
Number of subjects: 48
Study 32795310 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) 25 mL/day for 6 weeks
Number of subjects: 48
Study 35526010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and progressive rehabilitation and care across sectors including 12 weeks of progressive resistance exercises initiated 1–2 days after discharge, outreach nurse assessment, and a hotline for medical advice
Number of subjects: 50
Study 35526010 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation and care
Number of subjects: 50
Study 34322782 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal attentional focus
Number of subjects: 45
Study 34322782 — intervention group
Group type: EXPERIMENTAL
Intervention: External attentional focus
Number of subjects: 45
Study 34322782 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 35180696 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VIM (tractography-based targeting of the ventral intermediate nucleus)
Number of subjects: 0
Study 35180696 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VIM
Number of subjects: 0
Study 33438825 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational-counseling program based on precede-proceed model during pregnancy
Number of subjects: 130
Study 33438825 — intervention group
Group type: COMPARATOR
Intervention: Routine pregnancy care (Control)
Number of subjects: 130
Study 32111244 — intervention group
Group type: EXPERIMENTAL
Intervention: Decolonisation for Methicillin Sensitive Staphylococcus aureus (MSSA) to reduce post‐operative infection (QIST: Infection)
Number of subjects: 40
Study 32111244 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia optimisation programme to reduce peri‐operative blood transfusions (QIST: Anaemia)
Number of subjects: 40
Study 32111244 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group for QIST: Infection)
Number of subjects: 40
Study 32111244 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group for QIST: Anaemia)
Number of subjects: 40
Study 32111244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level secondary outcomes
Number of subjects: 40
Study 33506521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT) orientated anger management training
Number of subjects: 0
Study 33686040 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel
Number of subjects: 30
Study 33686040 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgery
Number of subjects: 30
Study 33686040 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (Biolase)
Number of subjects: 30
Study 35158207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 162
Study 34261408 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 298
Study 34261408 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal ideation
Number of subjects: 298
Study 34261408 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 298
Study 34261408 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive symptom scores
Number of subjects: 298
Study 34261408 — intervention group
Group type: COMPARATOR
Intervention: Negative symptoms
Number of subjects: 298
Study 34261408 — intervention group
Group type: COMPARATOR
Intervention: Social functioning
Number of subjects: 298
Study 34371884 — intervention group
Group type: EXPERIMENTAL
Intervention: tRES-HESP treatment
Number of subjects: 0
Study 34371884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35044692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge preservation performed after tooth extraction
Number of subjects: 57
Study 34167959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerinetide
Number of subjects: 1099
Study 32561125 — intervention group
Group type: COMPARATOR
Intervention: Symptoms listed in the NICE guidelines
Number of subjects: 574
Study 32561125 — intervention group
Group type: COMPARATOR
Intervention: Modified Goff Index symptoms
Number of subjects: 574
Study 32561125 — intervention group
Group type: COMPARATOR
Intervention: Each additional presenting symptom
Number of subjects: 574
Study 32561125 — intervention group
Group type: COMPARATOR
Intervention: Abdominal pain and loss of appetite/feeling full
Number of subjects: 574
Study 36006634 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor therapy
Number of subjects: 0
Study 36006634 — intervention group
Group type: COMPARATOR
Intervention: Reference category
Number of subjects: 0
Study 33641601 — intervention group
Group type: EXPERIMENTAL
Intervention: Calciphylaxis patients (20 patients)
Number of subjects: 60
Study 33641601 — intervention group
Group type: COMPARATOR
Intervention: Non-calciphylaxis patients (40 patients)
Number of subjects: 60
Study 32248190 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium (5 μg, two inhalations of 2.5 μg) for at least 2 weeks before esophagectomy and continued until postoperative evaluation
Number of subjects: 32
Study 32248190 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 32
Study 36294026 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity burden (measured by SPI-II)
Number of subjects: 97
Study 36294026 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI-II risk groups (low, medium, high)
Number of subjects: 97
Study 36294026 — intervention group
Group type: COMPARATOR
Intervention: Individual comorbid conditions
Number of subjects: 97
Study 34919613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 43
Study 34919613 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 43
Study 34919613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 43
Study 34184315 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 96
Study 34184315 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 96
Study 32067040 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV infection in infants at week 50
Number of subjects: 201
Study 32067040 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV DNA testing in infants
Number of subjects: 201
Study 32067040 — intervention group
Group type: EXPERIMENTAL
Intervention: Shedding of EBV in breast milk
Number of subjects: 201
Study 32067040 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV infant infection at week 50
Number of subjects: 201
Study 32067040 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical SAEs in infants
Number of subjects: 201
Study 33528457 — intervention group
Group type: EXPERIMENTAL
Intervention: ionic‐sonic electric toothbrush
Number of subjects: 78
Study 33528457 — intervention group
Group type: COMPARATOR
Intervention: manual toothbrush
Number of subjects: 78
Study 32358544 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (empagliflozin)
Number of subjects: 0
Study 32358544 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 0
Study 35659328 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal ARDS
Number of subjects: 360
Study 35659328 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-focal ARDS
Number of subjects: 360
Study 35659328 — intervention group
Group type: EXPERIMENTAL
Intervention: McCabe score
Number of subjects: 360
Study 35659328 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 360
Study 34597366 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib + low-dose ara-C (LDAC)
Number of subjects: 202
Study 34597366 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ara-C (LDAC) alone
Number of subjects: 202
Study 34597366 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib + LDAC
Number of subjects: 202
Study 32389019 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 55
Study 32389019 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 55
Study 35297467 — intervention group
Group type: EXPERIMENTAL
Intervention: 5g PHGG mixed with 200ml water per day for 4 weeks
Number of subjects: 52
Study 35297467 — intervention group
Group type: COMPARATOR
Intervention: 200ml water for 4 weeks (Control)
Number of subjects: 52
Study 35297467 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 52
Study 32630786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. longum OLP-01 (1.5 × 10^10 CFU/day)
Number of subjects: 21
Study 32630786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 36180953 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 368
Study 36180953 — intervention group
Group type: COMPARATOR
Intervention: Standard Moist Wound Care (SMWC)
Number of subjects: 368
Study 34175999 — intervention group
Group type: EXPERIMENTAL
Intervention: EUCAST guidelines
Number of subjects: 237
Study 34175999 — intervention group
Group type: COMPARATOR
Intervention: CLSI guidelines
Number of subjects: 237
Study 34175999 — intervention group
Group type: EXPERIMENTAL
Intervention: Disk diffusion according to EUCAST guidelines
Number of subjects: 237
Study 32160891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 612
Study 32160891 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (RT)
Number of subjects: 612
Study 33526448 — intervention group
Group type: EXPERIMENTAL
Intervention: Journals with strict CONSORT endorsement (BMJ and JAMA)
Number of subjects: 258
Study 33526448 — intervention group
Group type: EXPERIMENTAL
Intervention: Journals with less strict CONSORT endorsement (NEJM and Ann Intern Med)
Number of subjects: 258
Study 33526448 — intervention group
Group type: EXPERIMENTAL
Intervention: The Lancet
Number of subjects: 258
Study 33526448 — intervention group
Group type: COMPARATOR
Intervention: Journals that recommend adherence to CONSORT
Number of subjects: 258
Study 33526448 — intervention group
Group type: EXPERIMENTAL
Intervention: Journals that require a completed checklist for CONSORT adherence
Number of subjects: 258
Study 33526448 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RCTs
Number of subjects: 258
Study 33371851 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training program (8 sessions over one month)
Number of subjects: 92
Study 33371851 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 92
Study 33902162 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude of 2,590 m
Number of subjects: 35
Study 33902162 — intervention group
Group type: EXPERIMENTAL
Intervention: COPDDesat (SpO2 <90% for >30% of night‐time)
Number of subjects: 35
Study 32595159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG plus usual care
Number of subjects: 0
Study 32595159 — intervention group
Group type: COMPARATOR
Intervention: Usual care without probiotics
Number of subjects: 0
Study 34142915 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills training intervention (9 sessions)
Number of subjects: 80
Study 34142915 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study 34235908 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 36
Study 34235908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 36
Study 32224420 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day self-reported nicotine patch use
Number of subjects: 198
Study 32224420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week self-reported nicotine patch use
Number of subjects: 198
Study 32224420 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-week self-reported nicotine patch use
Number of subjects: 198
Study 32224420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day self-reported nicotine patch use
Number of subjects: 198
Study 33655432 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation (220 mg/day, containing 50 mg Zn) for 8 weeks
Number of subjects: 46
Study 33655432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (220 mg corn starch) for 8 weeks
Number of subjects: 46
Study 34048947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus GP
Number of subjects: 357
Study 34048947 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus GP
Number of subjects: 357
Study 32485095 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate (TE) 50, 125, 300, or 600 mg/week plus placebo for 20 weeks in 5aR trial
Number of subjects: 180
Study 32485095 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate (TE) 100 mg/week plus placebo for 6 months in OPTIMEN trial
Number of subjects: 180
Study 35078438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator (usual care + Patient Navigator)
Number of subjects: 45
Study 35078438 — intervention group
Group type: COMPARATOR
Intervention: Control condition (usual care)
Number of subjects: 45
Study 33183908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use during treatment
Number of subjects: 302
Study 33183908 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency to cannabis dependence
Number of subjects: 302
Study 33183908 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of cannabis use onset
Number of subjects: 302
Study 35753816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized corticoperiosteal bone flap with only arterial anastomosis (Group B)
Number of subjects: 49
Study 35753816 — intervention group
Group type: COMPARATOR
Intervention: Vascularized corticoperiosteal bone flap with both arterial and venous anastomosis (Group A)
Number of subjects: 49
Study 32917948 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention involving 36 phone calls and three home visits over 2 years
Number of subjects: 410
Study 32917948 — intervention group
Group type: COMPARATOR
Intervention: Usual post-discharge care (Control)
Number of subjects: 410
Study 32465052 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ CD57+ PD1+ T cells frequency above 7.8% in BAL
Number of subjects: 50
Study 32465052 — intervention group
Group type: COMPARATOR
Intervention: CD4+ CD57+ PD1+ T cells frequency
Number of subjects: 50
Study 35457474 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Inside Out (PIO) intervention
Number of subjects: 359
Study 35457474 — intervention group
Group type: COMPARATOR
Intervention: services-as-usual (control)
Number of subjects: 359
Study 33985364 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg plus hydrochlorothiazide 12.5 mg daily (active treatment)
Number of subjects: 12705
Study 33985364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily (active treatment)
Number of subjects: 12705
Study 33985364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of candesartan plus hydrochlorothiazide and rosuvastatin (active treatment)
Number of subjects: 12705
Study 33985364 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (control)
Number of subjects: 12705
Study 32791295 — intervention group
Group type: EXPERIMENTAL
Intervention: a-PDT with toluidine blue (TB)
Number of subjects: 21
Study 32791295 — intervention group
Group type: COMPARATOR
Intervention: Irrigation with normal saline
Number of subjects: 21
Study 35658056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) for 3 weeks
Number of subjects: 11
Study 35658056 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate low-fat diet (HCLF) for 3 weeks
Number of subjects: 11
Study 33381989 — intervention group
Group type: EXPERIMENTAL
Intervention: Core strength training for 10 weeks
Number of subjects: 48
Study 33381989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 35950355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (group A, n=30)
Number of subjects: 89
Study 35950355 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival scaling with vitamin C (group C, n=29)
Number of subjects: 89
Study 35950355 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (group B, n=30)
Number of subjects: 89
Study 33201520 — intervention group
Group type: COMPARATOR
Intervention: Org 48,775-0 (30 mg)
Number of subjects: 0
Study 33201520 — intervention group
Group type: COMPARATOR
Intervention: Org 48,775-0 (70 mg)
Number of subjects: 0
Study 33201520 — intervention group
Group type: COMPARATOR
Intervention: Org 48,775-0 (150 mg)
Number of subjects: 0
Study 33201520 — intervention group
Group type: COMPARATOR
Intervention: Org 48,775-0 (≥30 mg)
Number of subjects: 0
Study 33201520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33327312 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs, 640 mg t.i.d during chemotherapy and 1 month after treatment
Number of subjects: 179
Study 33327312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 35570329 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (8 mg)
Number of subjects: 95
Study 35570329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (8 mg)
Number of subjects: 95
Study 35570329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (both routes)
Number of subjects: 95
Study 32599655 — intervention group
Group type: EXPERIMENTAL
Intervention: idelalisib + anti-CD20 (rituximab or ofatumumab)
Number of subjects: 481
Study 32599655 — intervention group
Group type: COMPARATOR
Intervention: anti-CD20 alone
Number of subjects: 481
Study 32599655 — intervention group
Group type: EXPERIMENTAL
Intervention: idelalisib + anti-CD20
Number of subjects: 481
Study 35287430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose COH04S1 (1·0×10^7 PFU)
Number of subjects: 56
Study 35287430 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose COH04S1 (1·0×10^8 PFU)
Number of subjects: 56
Study 35287430 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose COH04S1 (2·5×10^8 PFU)
Number of subjects: 56
Study 35287430 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose COH04S1 followed by placebo
Number of subjects: 56
Study 35287430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56